Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The disease is often diagnosed after wide-spread dissemination, and the standard treatment combines aggressive surgery with platinum-based chemotherapy; however, most patients experience relapse in the form of peritoneal carcinom...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-12, Vol.15 (23), p.5694
Main Authors: Rodriguez, Galaxia M, Yakubovich, Edward, Vanderhyden, Barbara C
Format: Article
Language:English
Subjects:
Antigen presentation
Antigens
B cells
Cancer
Cancer immunotherapy
Cancer therapies
Catalysts
Chemotherapy
Cytokines
Development and progression
Genes
Health aspects
Immunity
Immunogenicity
Immunotherapy
Lymphocytes
Major histocompatibility complex
Medical prognosis
Mutation
Ovarian cancer
Patients
Peptides
Prognosis
Proteins
Stem cells
T cell receptors
Tumor microenvironment
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The disease is often diagnosed after wide-spread dissemination, and the standard treatment combines aggressive surgery with platinum-based chemotherapy; however, most patients experience relapse in the form of peritoneal carcinomatosis, resulting in a 5-year mortality below 45%. There is clearly a need for the development of novel treatments and cancer immunotherapies offering a different approach. Immunotherapies have demonstrated their efficacy in many types of cancers; however, only
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15235694